ArticleBMC medical ethics2021
Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices.
Article in BMC medical ethics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Open Science Practices in Systematic Reviews From 2014 to 2024: A Cohort Study of 300 Systematic Reviews.Cochrane evidence synthesis and methods · 2026Article
- Editorial: Tips for early career researchers (ECRs) in searching the literature and in academic publishing.Parasitology · 2026Article
- How COVID-19 affected academic publishing: a 3-year study of 17 million research papers.International journal of epidemiology · 2025Article
- Peer Review inJAACAP open · 2023Article
- Scope and financial impact of unpublished data and unused samples among U.S. academic and government researchers.iScience · 2023Article
- Management of Multisystem Inflammatory Syndrome in Children: Decision-Making Regarding a New Condition in the Absence of Clinical Trial Data.The Canadian journal of cardiology · 2023Review
- Responsible dissemination of health and medical research: some guidance points.BMJ evidence-based medicine · 2023Article
- COVID-19 retracted publications on retraction watch: A systematic survey of their pre-prints and citations.Heliyon · 2023Article
- Using an expert survey and user feedback to construct PRECHECK: A checklist to evaluate preprints on COVID-19 and beyond.F1000Research · 2023Article
- Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance.Epidemics · 2022Article
- Forecasting the publication and citation outcomes of COVID-19 preprints.Royal Society open science · 2022Article
- Reliability of citations of medRxiv preprints in articles published on COVID-19 in the world leading medical journals.PloS one · 2022Article
- Governance frameworks for COVID-19 research ethics review and oversight in Latin America: an exploratory study.BMC medical ethics · 2021Article
- Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials.Annals of intensive care · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over recent years, the research community has been increasingly using preprint servers to share manuscripts that are not yet peer-reviewed. Even if it enables quick dissemination of research findings, this practice raises several challenges in publication ethics and integrity. In particular, preprints have become an important source of information for stakeholders interested in COVID19 research developments, including traditional media, social media, and policy makers. Despite caveats about their nature, many users can still confuse pre-prints with peer-reviewed manuscripts. If unconfirmed but already widely shared first-draft results later prove wrong or misinterpreted, it can be very difficult to "unlearn" what we thought was true. Complexity further increases if unconfirmed findings have been used to inform guidelines. To help achieve a balance between early access to research findings and its negative consequences, we formulated five recommendations: (a) consensus should be sought on a term clearer than 'pre-print', such as 'Unrefereed manuscript', "Manuscript awaiting peer review" or ''Non-reviewed manuscript"; (b) Caveats about unrefereed manuscripts should be prominent on their first page, and each page should include a red watermark stating 'Caution-Not Peer Reviewed'; (c) pre-print authors should certify that their manuscript will be submitted to a peer-review journal, and should regularly update the manuscript status; (d) high level consultations should be convened, to formulate clear principles and policies for the publication and dissemination of non-peer reviewed research results; (e) in the longer term, an international initiative to certify servers that comply with good practices could be envisaged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.